Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bastholt

Showing results (11-20 of 134) with videos related to

Pageof 14
Sort By:
Ugeskrift for Laeger|September 6, 2016
[Treatment of BRAF-mutated metastatic melanoma]Tessa Bystrup Boyles, Inge Marie Svane, Lars Bastholt, et al.
Ugeskrift for Laeger|October 11, 2017
[Immunotherapy is cancer treatment with a novel side-effect profile]Maria Kondrup, Louise Raunkilde, Inge Marie Svane, et al.
International Journal of Cancer|August 20, 2019
The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneousEva Ellebaek, Lars Bastholt, Henrik Schmidt, et al.
Melanoma Research|November 3, 2012
Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanomaRuta Zukauskaite, Henrik Schmidt, Jon T Asmussen, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2005
Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patientsOlfred Hansen, Susanne Larsen, Lars Bastholt, et al.
Journal of Patient-Reported Outcomes|January 21, 2022
Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trialLærke K Tolstrup, Helle Pappot, Lars Bastholt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2019
Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanomaLars Bastholt, Henrik Schmidt, Jon Kroll Bjerregaard, et al.
Acta Oncologica (Stockholm, Sweden)|November 11, 2016
Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanomaMathilde Weisz Ejlsmark, Charlotte Kristiansen, Jesper Grau Eriksen, et al.
European Thyroid Journal|May 22, 2014
A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancerBirte Nygaard, Lars Bastholt, Finn Noe Bennedbæk, et al.
Journal of Patient-Reported Outcomes|March 23, 2019
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapyLærke K Tolstrup, Lars Bastholt, Ann-Dorthe Zwisler, et al.
Pageof 14

Showing results (11-20 of 134) with videos related to

Sort By:
Pageof 14
Ugeskrift for Laeger|September 6, 2016
[Treatment of BRAF-mutated metastatic melanoma]Tessa Bystrup Boyles, Inge Marie Svane, Lars Bastholt, et al.
Ugeskrift for Laeger|October 11, 2017
[Immunotherapy is cancer treatment with a novel side-effect profile]Maria Kondrup, Louise Raunkilde, Inge Marie Svane, et al.
International Journal of Cancer|August 20, 2019
The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneousEva Ellebaek, Lars Bastholt, Henrik Schmidt, et al.
Melanoma Research|November 3, 2012
Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanomaRuta Zukauskaite, Henrik Schmidt, Jon T Asmussen, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2005
Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patientsOlfred Hansen, Susanne Larsen, Lars Bastholt, et al.
Journal of Patient-Reported Outcomes|January 21, 2022
Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trialLærke K Tolstrup, Helle Pappot, Lars Bastholt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2019
Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanomaLars Bastholt, Henrik Schmidt, Jon Kroll Bjerregaard, et al.
Acta Oncologica (Stockholm, Sweden)|November 11, 2016
Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanomaMathilde Weisz Ejlsmark, Charlotte Kristiansen, Jesper Grau Eriksen, et al.
European Thyroid Journal|May 22, 2014
A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancerBirte Nygaard, Lars Bastholt, Finn Noe Bennedbæk, et al.
Journal of Patient-Reported Outcomes|March 23, 2019
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapyLærke K Tolstrup, Lars Bastholt, Ann-Dorthe Zwisler, et al.
Pageof 14